Paul A. Friedman, M.D., CEO of Madrigal Pharmaceuticals, has a strong background in medicine and a notable career in the biopharmaceutical industry. He graduated from the University of Pennsylvania School of Medicine and has held influential roles at major companies...
Paul A. Friedman, M.D., CEO of Madrigal Pharmaceuticals, has a strong background in medicine and a notable career in the biopharmaceutical industry. He graduated from the University of Pennsylvania School of Medicine and has held influential roles at major companies like Incyte Corporation, where he was CEO from 2001 to 2014. Under his leadership at Madrigal Pharmaceuticals since the merger in 2016, the company has focused on developing new therapies for diseases like fatty liver disease. He's in a unique position, holding a significant number of shares in Madrigal, with reports showing fluctuations in his holdings worth up to $35.66 million back in September 2019 and peaking at about $48.06 million in December 2022. In 2023, his total compensation reached approximately $9.56 million, although he did not receive a bonus this year due to unmet performance metrics. Notably, Friedman is married to Rebecca Taub, a fellow executive at the company, which adds a personal connection to his professional pursuits. His extensive experience in both medicine and leadership roles contributes to his strategic decisions in steering Madrigal towards success amid the complex landscape of the pharmaceutical industry.